Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tempest TherapeuticsTPST -1.90%31 Operating Cash Flow per Share is $-3.13 as of Jun. 2026. GuruFocus rates TPST with a GF Score™ of 31/100. The stock has 1 warning sign investors should review. Among 1,135 Biotechnology companies, Tempest Therapeutics ranks better than 79.47% on this metric.
Tempest Therapeutics's operating cash flow per share for the
three
months ended in Jun. 2026 was $-0.18.
Tempest Therapeutics's operating cash flow per share for the trailing twelve months (TTM) ended in Jun. 2026 was $-3.13.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 43.10% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 33.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Tempest Therapeutics's Operating Cash Flow per Share or its related term are showing as below:
TPST'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: 14.8 Med: 43.1 Max: 44.3
Current: 43.1
During the past 6 years, Tempest Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 44.30% per year. The lowest was 14.80% per year. And the median was 43.10% per year.
TPST's 3-Year OCF Growth Rate is ranked better than 79.47% of 1135
companies
in the Biotechnology industry
Industry Median: 17
vs TPST: 43.10
Tempest Therapeutics Operating Cash Flow per Share Related Terms
Tempest Therapeutics Operating Cash Flow per Share Historical Data
* Premium members only.
The historical data trend for Tempest Therapeutics's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tempest Therapeutics Operating Cash Flow per Share Chart
TPST vs LPCN, CYCN, BCDA: Operating Cash Flow per Share Comparison
For the Biotechnology subindustry, Tempest Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tempest Therapeutics Price-to-Operating-Cash-Flow vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tempest Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Tempest Therapeutics's Price-to-Operating-Cash-Flow falls into.
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.13
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Operating Cash Flow per Share of $-3.13 mean?
Tempest Therapeutics (TPST) has a Operating Cash Flow per Share of $-3.13 as of Jun. 2026. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Tempest Therapeutics and its competitors. According to the industry distribution chart, Tempest Therapeutics ranks #233 out of 1135 companies in the Biotechnology industry, placing it in the top 20.5%.
Is Tempest Therapeutics' Operating Cash Flow per Share too high?
Tempest Therapeutics' current Operating Cash Flow per Share is $-3.13. Based on the distribution chart, Tempest Therapeutics ranks #233 out of 1135 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Tempest Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Tempest Therapeutics' Operating Cash Flow per Share compare to LPCN and CYCN?
According to the Biotechnology industry distribution chart, Tempest Therapeutics ranks #233 out of 1135 companies for Operating Cash Flow per Share. This places Tempest Therapeutics in the top 21% of its industry — outperforming the majority of peers. The industry median Operating Cash Flow per Share is 17.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Cash Flow per Share for a Biotechnology company?
The median Operating Cash Flow per Share among Biotechnology companies is 17.00, based on 1,135 companies in the industry. Companies in the top quartile (top 25%) have a Operating Cash Flow per Share significantly above this median, while those in the bottom quartile fall well below. However, Operating Cash Flow per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Cash Flow per Share mean?
A high Operating Cash Flow per Share can signal that a stock is expensive relative to its fundamentals. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Tempest Therapeutics and its competitors. For the Biotechnology industry, the median Operating Cash Flow per Share is 17.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tempest Therapeutics's current Operating Cash Flow per Share is $-3.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tempest Therapeutics stock overvalued right now?
Tempest Therapeutics (TPST) has a current Operating Cash Flow per Share of $-3.13. The current Operating Cash Flow per Share is $-3.13. Tempest Therapeutics' overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Cash Flow per Share calculated?
Operating Cash Flow per Share is calculated from a company's financial statements. For Tempest Therapeutics (TPST), the current Operating Cash Flow per Share is $-3.13 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.
31GF Score
Get the complete analysis for TPST
Operating Cash Flow per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPST has been successfully added to your 
